Literature DB >> 28228316

Gonadotropin-releasing hormone analogue as sole luteal support in antagonist-based assisted reproductive technology cycles.

Itai Bar Hava1, Moran Blueshtein2, Hadas Ganer Herman3, Yeela Omer1, Gila Ben David1.   

Abstract

OBJECTIVE: To evaluate the efficacy of GnRH agonists (GnRH-a) as sole luteal phase support in patients undergoing IVF in antagonist-based cycles compared with standard vaginal P preparations.
DESIGN: Retrospective cohort.
SETTING: Private fertility clinic. PATIENT(S): Patients who underwent antagonist-based cycles performed at our clinic between 2009 and 2015. INTERVENTION(S): Intranasal GnRH-a or vaginal P as luteal support. MAIN OUTCOME MEASURE(S): Live birth rates. RESULT(S): A total of 2,529 antagonist-based cycles from 1,479 women were available for analysis, in which GnRH-a were used in 1,436 cycles (56.7%) and P supplementation in 1,093 cycles (43.2%). Significantly higher live birth rates were demonstrated for the entire GnRH-a group compared with the P group. This result was even more prominent when women older than 35 years were considered separately. Furthermore, after adjustment for age, body mass index (BMI), past obstetric history, number of IVF cycles, oocyte retrieved and embryos transferred, GnRH-a was still associated with a higher rate of live birth (odds ratio 1.46, 95% confidence interval 1.10-1.94). Once a positive β-hCG was achieved, chemical pregnancy rates (PRs) and miscarriage rates were not statistically different between the GnRH-a and the P supplementation group, and GnRH-a was associated with a higher rate of live births (odds ratio 1.59, 95% confidence interval 1.07-2.36). CONCLUSION(S): This large retrospective study suggests that repeated intranasal GnRH-a for luteal phase support is associated with a higher live birth rate compared with standard P supplementations.
Copyright © 2016 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  GnRH analogue; in vitro fertilization (IVF); live birth rate; luteal phase support; pregnancy

Mesh:

Substances:

Year:  2016        PMID: 28228316     DOI: 10.1016/j.fertnstert.2016.10.011

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  9 in total

1.  In reply to: Christ J, Herndon CN, Yu B. Severe ovarian hyperstimulation syndrome associated with long-acting GnRH agonist in oncofertility patients. J Assist Reprod Genet. 2021;38:751-6. doi:10.1007/s10815-020-02051.

Authors:  Avi Tsafrir; Ariel Weissman
Journal:  J Assist Reprod Genet       Date:  2021-08-25       Impact factor: 3.357

2.  Impact of Mid-Luteal Phase GnRH Agonist Administration on Reproductive Outcomes in GnRH Agonist-Triggered Cycles: A Randomized Controlled Trial.

Authors:  Abdelhamid Benmachiche; Sebti Benbouhedja; Abdelali Zoghmar; Amel Boularak; Peter Humaidan
Journal:  Front Endocrinol (Lausanne)       Date:  2017-06-15       Impact factor: 5.555

3.  Comparison of PGS2.0 versus conventional embryo morphology evaluation for patients with recurrent pregnancy loss: a study protocol for a multicentre randomised trial.

Authors:  Caixia Lei; Yilun Sui; Jiangfeng Ye; Yao Lu; Ji Xi; Yun Sun; Li Jin; Xiaoxi Sun
Journal:  BMJ Open       Date:  2020-10-07       Impact factor: 2.692

Review 4.  Gonadotropin-releasing hormone agonist for ovulation trigger - OHSS prevention and use of modified luteal phase support for fresh embryo transfer.

Authors:  Juan Carlos Castillo; Thor Haahr; María Martínez-Moya; Peter Humaidan
Journal:  Ups J Med Sci       Date:  2020-05-04       Impact factor: 2.384

5.  A 10-year follow-up on the practice of luteal phase support using worldwide web-based surveys.

Authors:  Gon Shoham; Milton Leong; Ariel Weissman
Journal:  Reprod Biol Endocrinol       Date:  2021-01-26       Impact factor: 5.211

6.  Predictive Factors for Live Birth in Fresh In Vitro Fertilization/Intracytoplasmic Sperm Injection Treatment in Poor Ovarian Reserve Patients Classified by the POSEIDON Criteria.

Authors:  Fei Li; Tian Ye; Huijuan Kong; Jing Li; Linli Hu; HaiXia Jin; YiHong Guo; Gang Li
Journal:  Front Endocrinol (Lausanne)       Date:  2021-04-12       Impact factor: 5.555

7.  Single Dose Gonadotropin-Releasing Hormone Agonist Luteal Support in Fresh Embryo Transfer: Variation in Timing, Type, and Dosage.

Authors:  Muhammad Azrai Abu; Jojinah Vindah Alexander; Abdul Kadir Abdul Karim; Mohd Faizal Ahmad; Mohd Hashim Omar
Journal:  Front Med (Lausanne)       Date:  2022-02-17

Review 8.  Individualized luteal phase support after fresh embryo transfer: unanswered questions, a review.

Authors:  Jing Zhao; Jie Hao; Yanping Li
Journal:  Reprod Health       Date:  2022-01-22       Impact factor: 3.223

9.  Efficacy of daily GnRH agonist for luteal phase support following GnRH agonist triggered ICSI cycles versus conventional strategy: A Randomized controlled trial.

Authors:  Saghar Salehpour; Leila Nazari; Sedighe Hosseini; Elham Azizi; Nasrin Borumandnia; Teibeh Hashemi
Journal:  JBRA Assist Reprod       Date:  2021-07-21
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.